We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Agenus Inc (AGEN) Com Stk USD0.01

Sell:$0.67 Buy:$0.67 Change: $0.0099 (1.48%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.0099 (1.48%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.0099 (1.48%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. The Company is focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company’s I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company’s antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.

Contact details

3 Forbes Rd
United States
+1 (781) 6744400

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$286.58 million
Shares in issue:
381.50 million
United States
US dollar

Key personnel

  • Garo Armen
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Christine Klaskin
    Vice President - Finance
  • Manuel Duenas
    Head of Market Access
  • Stephanie Fagan
    Chief Communications Officer
  • Benny Johnson
    Senior Medical Director
  • Steven O'Day
    Chief Medical Officer
  • Robin Taylor
    Chief Commercial Officer
  • Homa Yeganegi
    Chief Product Strategy and Global Medical Affairs Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.